ReviewCancer immunology, immunotherapy : CII2018
Mucosa-associated invariant T cells in malignancies: a faithful friend or formidable foe?
Review in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Mining the multifunction of mucosal-associated invariant T cells in hematological malignancies and transplantation immunity: A promising hexagon soldier in immunomodulatory.Frontiers in immunology · 2022Pooled it
- Immunophenotyping of Mouse Colonic Unconventional T Cells by Mapping Cell Phenomics With 22-Color Flow Cytometry Assays.Phenomics (Cham, Switzerland) · 2025Article
- MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment.Journal for immunotherapy of cancer · 2025Article
- Interplay between innate-like T-cells and microRNAs in cancer immunity.Discover oncology · 2025Review
- Tissue-resident immune cells: from defining characteristics to roles in diseases.Signal transduction and targeted therapy · 2025Review
- Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential.Frontiers in immunology · 2024Review
- MAIT cells in bacterial infectious diseases: heroes, villains, or both?Clinical and experimental immunology · 2023Review
- Multi-Faceted Role of Cancer-Associated Adipocytes in Colorectal Cancer.Biomedicines · 2023Review
- Classic costimulatory interactions in MAIT cell responses: from gene expression to immune regulation.Clinical and experimental immunology · 2023Article
- TIME Is Ticking for Cervical Cancer.Biology · 2023Review
- Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2023Article
- Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy.Journal for immunotherapy of cancer · 2023Article
- MAIT cells and their implication in human oral diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues.Cancer immunology, immunotherapy : CII · 2022Article
- MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations.Cancer immunology, immunotherapy : CII · 2022Article
- Advances in NK cell production.Cellular & molecular immunology · 2022Review
- The P5-type ATPase ATP13A1 modulates major histocompatibility complex I-related protein 1 (MR1)-mediated antigen presentation.The Journal of biological chemistry · 2022Article
- Participation of Increased Circulating MAIT Cells in Lung Cancer: a Pilot Study.Journal of Cancer · 2022Article
- Involvement of impaired CD8Reproductive biology and endocrinology : RB&E · 2021Article
- Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response.Cancer immunology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Mucosa-associated invariant T (MAIT) cells are a subset of innate-like T lymphocytes known for their ability to respond to MHC-related protein 1 (MR1)-restricted stimuli and select cytokine signals. They are abundant in humans and especially enriched in mucosal layers, common sites of neoplastic transformation. MAIT cells have been found within primary and metastatic tumors. However, whether they promote malignancy or contribute to anticancer immunity is unclear. On the one hand, MAIT cells produce IL-17A in certain locations and under certain circumstances, which could in turn facilitate neoangiogenesis, intratumoral accumulation of immunosuppressive cell populations, and cancer progression. On the other hand, they can express a potent arsenal of cytotoxic effector molecules, NKG2D and IFN-γ, all of which have established roles in cancer immune surveillance. In this review, we highlight MAIT cells' characteristics as they might pertain to cancer initiation, progression, or control. We discuss recent findings, including our own, that link MAIT cells to cancer, with a focus on colorectal carcinoma, as well as some of the outstanding questions in this active area of research. Finally, we provide a hypothetical picture in which MAIT cells constitute attractive targets in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.